Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy

Circulation

Volumn 97, Issue 17, 1998, Pages 1708-1715

  Thomas, Chadwick V ^a   Coker, Mytsi L ^a   Zellner, James L ^a   Handy, John R ^a   Crumbley III, A Jackson ^a   Spinale, Francis G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cardiomyopathy; Enzymes; Myocardium

Indexed keywords

COLLAGENASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HEART DILATATION; HEART LEFT VENTRICLE MUSCLE; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; PRIORITY JOURNAL;

EID: 0032485851     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.17.1708     Document Type: Article

References (45)

1. Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels W, Abelmann WH, Harlan WR. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop). Am J Cardiol. 1992;69:1458-1466.
2. Seward JB, Tajik AJ. Primary cardiomyopathies: classification, pathophysiology, clinical recognition and management. Cardiovasc Clin. 1980;10:199-230.
3. Parmley WW. Pathophysiology of congestive heart failure. Am J Cardiol. 1985;56:7A-11A.
4. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation. 1993;87:VI-17-VI-23.
5. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV, Mendelsohn FAO, Motz WH, Mulvany MJ, Strauer BE. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992;20:3-16.
6. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83: 1849-1865.
7. Poole-Wilson PA. Relation of pathophysiological mechanisms to outcome in heart failure. J Am Coll Cardiol. 1993;22:22A-29A.
8. Tomita M, Spinale FG, Crawford FA, Zile MR. Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia induced cardiomyopathy: disparity between recovery of systolic versus diastolic function. Circulation. 1991;83:635-644.
9. Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during the development and recovery from supraventricular tachycardia. Am J Physiol. 1991;261:H308-H318.
10. Weber KT, Pick R, Janicki JS, Gadodia G, Lakier JB. Inadequate collagen tethers in dilated cardiomyopathy. Am Heart J. 1988;116:1641-1646.
11. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: role of metalloproteinases and pyridinoline cross links. Am J Pathol. 1996;148:1639-1648.
12. Werb Z, Alexander CM. Proteinases and matrix degradation. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. New York, NY: WB Saunders; 1993:248-268.
13. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol. 1996;148:1345-1350.
14. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
15. Tyagi SC, Kumar S, Voelker DJ, Ready HK, Janicki JS, Curtis JJ. Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem. 1996;63:185-198.
16. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem. 1996;155:13-21.
17. Armstrong PW, Moe GW, Howard RJ, Grima EA, Cruz TF. Structural remodelling in heart failure: gelatinase induction. Can J Cardiol. 1994; 10:214-220.
18. Tyagi SC, Kumar SG, Banks J, Fortson W. Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. J Mol Cell Cardiol. 1995;27:2177-2189.
19. Morodomi T, Ogata Y, Sasaguri Y, Morimatsu M, Nagase H. Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukemia and HT1080 fibrosarcoma cells. Biochem J. 1992;285:603-611.
20. Heussen C, Dowdle EB. Electrophoretic analysis of plamsinogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem. 1080:102;196-202.
21. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75:181-189.
22. Okada T, Gonoji Y, Naka K, Tomita K, Nakanishi I, Iwata K, Yamashita K, Hayakawa T. Matrix metalloproteinase 9 (92-kDa gellatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. J Biol Chem. 1992;267:21712-21719.
23. Nagase H, Enghild JJ, Suzuki K, Salvesen G. Stepwise activation mechanisms of the precursor of the matrix metalloproteinase 3 (stromelysin) by proteinases and mercuric acetate. Biochemistry. 1990;29:5783-5789.
24. Bjerrum OJ, Selmer JC, Lihme A. Native immunoblotting: transfer of membrane proteins in the presence of non-ionic detergent. Electrophoresis. 1987;8:388-397.
25. He C, Wilhelm SM, Pentland AP, Manner BL, Grant GA, Eisen AZ, Goldberg GI. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A. 1989;86:2632-2636.
26. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863-868.
27. Janicki JS, Matsubara BB. Myocardial collagen and left ventricular diastolic dysfunction. In: Gaash WH, LeWinter MM, eds. Left Ventricular Diastolic Dysfunction and Heart Failure. Philadelphia, Pa: Lea & Febinger; 1994:125-140.
28. Janicki JS, Henegar JR, Campbell SE, Tyagi SC. Myocardial collagenase activity in experimental dilated cardiomyopathy. In: Weber KT, ed. Wound Healing in Cardiovascular Disease. Armonk, NY: Futura Press; 1995:73-81.
29. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997;378:151-160.
30. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovesk J, Bumpus FM, Hussain A. Cellular localization and regional distribution of an angiotensin II forming chymase in the heart. J Clin Invest. 1995;95:1519-1527.
31. Shiota N, Jin D, Takai S, Kawamura T, Koyama M, Nakamura N, Miyazaki M. Chymase is activated in the hamster heart following ven tricular fibrosis during the chronic stage of hypertension. FEBS Lett. 1997;406:301-304.
32. Dell'Italia LJ, Meng QC, Balcells E, Straeter-Knowden IM, Hankes GH, Dillon R, Cartee RE, Orr R, Bishop SP, Oparil S, EIton TS. Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. Am J Physiol. 1995;269:H2065-H2073.
33. Ye QZ, Hupe D, Johnson L. Catalytic domains of matrix metalloproteinases: a molecular biology approach to drug discovery. Curr Med Chem. 1996;3:407-418.
34. Murphy G, Coclett MI, Stephens PE, Smith BJ, Docherty AJ. Stromelysin is an activator of procollagenase: a study with natural and recombinant enzymes. Biochem J. 1987;248:265-268.
35. Gruber BL, Marchese MJ, Suzuki K, Schwartz LB, Okada Y, Nagase H, Ramamurthy NS. Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J Clin Invest. 1989;84:1657-1662.
36. MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI. Discordinate expression of Stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts: synergistic effects of interleukin-1 and tumor necrosis factor-α on Stromelysin expression. J Biol Chem. 1990;265:17238-17245.
37. Marriott JB, Goldman JH, Keeling PJ, Baig MK, Dalgleish AG, McKenna WJ. Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart. 1996;75:287-290.
38. Munger MA, Johnson M, Amber U, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996;77:723-727.
39. Goldberg GI, Manner BL, Grant GA, Eisen AZ, Wilhelm S, He C. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteinase designated TIMP. Proc Natl Acad Sci U S A. 1989;86:8207-8211.
40. Cawston TE, Curry VA, Clark IM, Hazleman BL. Identification of a new metalloproteinase inhibitor that forms tight-binding complexes with collagenase. Biochem J. 1990;269:183-187.
41. Fujimoto N, Iwata K. Enzyme immunoassays for matrix metalloproteinases and their inhibitors. Connect Tissue Res. 1994;26:237-244.
42. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
43. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cordial. 1994;26:809-820.
44. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res. 1996;56:2815-2822.
45. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994;54:4726-4728.